A novel agent targeting APRIL: A new hope for elderly patients of IgA nephropathy
Sibeprenlimab is a humanized IgG2 monoclonal antibody that binds to and neutralizes the activity of APRIL. It should usher in a new era in the treatment of IgAN, especially in elderly patients.
Gorde:
| Egile Nagusiak: | , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Wiley
2025-02-01
|
| Saila: | Aging Medicine |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1002/agm2.12370 |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|